本文已被：浏览 529次 下载 306次
投稿时间：2020-03-14 网络发布日期：2020-12-20
投稿时间：2020-03-14 网络发布日期：2020-12-20
中文摘要: 目的 探讨胸腺肽治疗晚期宫颈癌化疗后骨髓抑制对患者生存期以及生存质量的影响。方法 选取2012年7月至2015年6月接受手术及同步化疗的晚期宫颈癌患者96例，按照治疗方法分为观察组(n=48)和对照组(n=48)。对照组给予同步化疗;观察组给予同步化疗+胸腺肽治疗。治疗4周后比较治疗效果，记录治疗前、治疗4周后免疫球蛋白G(Ig)G、IgA、IgM和生活质量、C反应蛋白(CRP)、自然杀伤细胞(NK)的变化，对比两组患者治疗后骨髓抑制情况以及生存率。结果 治疗后，观察组总有效率高于对照组(85.42% vs 62.50%，P<0.05);治疗后，两组患者IgG、IgA、IgM等水平均有升高，且观察组明显高于对照组(P<0.05，P<0.01);治疗后，两组患者躯体功能、情绪功能、认知功能、整体生活质量指标评分均有升高，且观察组明显高于对照组(P<0.05，P<0.01)。治疗后，两组患者CRP水平均有降低，观察组低于对照组(P<0.05，P<0.01);治疗后，两组患者NK细胞水平均有升高，且观察组高于对照组(P<0.05，P<0.01);治疗后，观察组患者骨髓抑制改善效果优于对照组(P<0.01);对患者进行为期3年随访，观察组患者1年、2年、3年生存率均高于对照组(P<0.05)。结论 胸腺肽辅助化疗治疗晚期宫颈癌，可调节患者免疫功能，抑制炎性因子表达，减轻患者骨髓抑制，提高疗效和患者生活质量，改善患者生存率。
Abstract:Objective To investigate the effect of thymosin on survival rate and quality of life of advanced cervical cancer patients with myelosuppression after chemotherapy. Methods A total of 96 patients with advanced cervical cancer who received chemotherapy from July 2012 to June 2015 were selected and divided into observation group (n=48) and control group (n=48) according to the treatment method.The control group was given synchronous chemotherapy, the observation group was given synchronous chemotherapy and thymosin treatment.The therapeutic effect was compared 4 weeks after treatment, and the changes of immunoglobulin(Ig)G, IgA, IgM, quality of life, C-reactive protein (CRP), natural killer cell(NK) were recorded before and 4 weeks after treatment.The bone marrow suppression and survival time of the two groups were compared. Results After treatment, the levels of IgG, IgA, and IgM in the two groups increased, and those were significantly higher of observation group than of control group (P<0.05, P<0.01).After treatment, the physical function, emotional function, cognitive function, and overall quality of life index scores in the two groups increased, and those were significantly higher in observation group than in control group (P<0.05, P<0.01).After treatment, the CRP levels of the two groups decreased, and that was lower of observation group than of control group (P<0.05, P<0.01).After treatment, the NK cell levels of the two groups increased, and that was higher of observation group than of control group (P<0.05, P<0.01). After treatment, the levels of NK cells in the two groups were increased, and the observation group was higher than the control group (P<0.05).After treatment, the improvement effect of bone marrow suppression in the observation group was better than that in the control group (P<0.05).The 1-year, 2-year and 3-year survival rates of observation group were higher than those of control group (P<0.05). Conclusion Thymosin adjuvant chemotherapy in patients with advanced cervical cancer has significant effect, can regulate the immune function of patients, inhibit the expression of inflammatory factors, reduce myelosuppression, improve the quality of life and survival rate of patients.
文章编号： 中图分类号：R737.33 文献标志码：B
基金项目:福建省自然科学基金计划项目(13161134)
| Author Name | Affiliation |
| CAO Hui*, LIANG Hui-xia | *Obstetrics and Gynecology Department, Xiang′an Hospital of Xiamen University, Xiamen, Fujian 361101, China |
引用文本：
曹晖,梁慧霞.胸腺肽对晚期宫颈癌化疗后骨髓抑制患者的疗效[J].中国临床研究,2020,33(12):1653-1656.
曹晖,梁慧霞.胸腺肽对晚期宫颈癌化疗后骨髓抑制患者的疗效[J].中国临床研究,2020,33(12):1653-1656.